TY - JOUR. T1 - Race/ethnic variations in ovarian cancer mortality in the United States, 1992-1997. AU - Howe, Holly L.. AU - Tung, Ko Hui. AU - Coughlin, Steven. AU - Jean-Baptiste, Rachel. AU - Hotes, Joellyn. PY - 2003/5/15. Y1 - 2003/5/15. N2 - Ovarian cancer is reported to be the most fatal malignancy of the female genital tract and the fifth leading cause of cancer deaths among women. In the current study, the authors describe ovarian cancer mortality by race and ethnicity in the U.S. during the years 1992-1997, a period comparable to the ovarian cancer incidence data presented in this supplement.. AB - Ovarian cancer is reported to be the most fatal malignancy of the female genital tract and the fifth leading cause of cancer deaths among women. In the current study, the authors describe ovarian cancer mortality by race and ethnicity in the U.S. during the years 1992-1997, a period comparable to the ovarian cancer incidence data presented in this supplement.. UR - ...
TY - JOUR. T1 - Aberrant non-canonical WNT pathway as key-driver of high-grade serous ovarian cancer development. AU - Zannoni, Gian Franco. PY - 2020. Y1 - 2020. N2 - Epithelial ovarian cancer (EOC), the deadliest among gynecologic malignancies, is ranked as the fifth leading cause of cancer deaths in females [1]. Based on morphological findings, cellular origins, clinical characteristics, and several molecular genetic/epigenetic alterations, EOC has been subdivided into five main types: high-grade serous (HGSC, 70%), endometrioid (EC, 10%), clear cell (CC, 10%), mucinous (MC, 3%), and low-grade serous carcinomas (LGSC, , 5%) that account for over 95% of cases [2]. HGSCs generally harbor TP53 alterations, a pronounced genomic instability and, also, inherited and somatic BRCA1 and BRCA2 mutations. The other abovementioned cancer types are frequently characterized by mutations in KRAS, BRAF, PTEN, and CTNNB1 (Beta-catenin), and a relatively stable karyotype [2]. In this complex and heterogeneous ...
Get Ovarian Cancer Treatment cost from certified hospitals in Kolkata. Get assistance from medical experts to select best hospital for Ovarian Cancer Treatment in Kolkata
TY - JOUR. T1 - Adenosine triphosphate-based chemotherapy response assay predicts long-Term survival of primary epithelial ovarian cancer. AU - Li, Lan Ying. AU - Kim, Sang Wun. AU - Nam, Eun Ji. AU - Lee, Jungyun. AU - Kim, Sunghoon. AU - Kim, Young Tae. PY - 2019/2/1. Y1 - 2019/2/1. N2 - Objective The aim of this study is to analyze the long-Term relapse-free survival and overall survival outcomes of primary ovarian cancer patients using adenosine triphosphate-based chemotherapy response analysis. Methods In total, 162 primary epithelial ovarian cancer patients who underwent chemotherapy response assay for carboplatin, cisplatin, and paclitaxel by adenosine triphosphate-based chemotherapy response analysis prior to chemotherapy between December 2006 and November 2016 were retrospectively reviewed. Chemosensitivity with single or combined three agents and clinical characteristics of patients were studied to understand their correlation with long-Term relapse-free survival and overall survival. ...
While ovarian cancer remains the most lethal gynecological malignancy in the United States, there are no biomarkers available that are able to predict therapeutic responses to ovarian malignancies. OVCAR3 cells were treated with EGF1, and the time course of cell progression was monitored based on Akt phosphorylation and growth dynamics. EGF-stimulated Akt phosphorylation was detected at 12 h post-treatment, but an impact on expansion was not really noticed until 48 l post-exposure. Growth-stimulated mobile lysates had been examined for proteins single profiles between treatment organizations and across period factors using iTRAQ marking and mass spectrometry. The proteins response to EGF treatment was determined via iTRAQ evaluation in EGF-stimulated lysates relatives to vehicle-treated individuals across the treatment period program. Approval research had been performed on one of the controlled aminoacids differentially, lysosomal-associated membrane layer INK 128 proteins 1 (Light-1), in human ...
Olaparib (PARP inhibitors) - Ovarian Cancer Treatment Olaparib (PARP inhibitors) - Ovarian Cancer Treatment Olaparib (PARP inhibitors) - Ovarian Cancer
Fingerprint Dive into the research topics of Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Together they form a unique fingerprint. ...
TY - JOUR. T1 - Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer. T2 - A report from the ovarian cancer association consortium. AU - Amankwah, Ernest K.. AU - Wang, Qinggang. AU - Schildkraut, Joellen M.. AU - Tsai, Ya Yu. AU - Ramus, Susan J.. AU - Fridley, Brooke L.. AU - Beesley, Jonathan. AU - Johnatty, Sharon E.. AU - Webb, Penelope M.. AU - Chenevix-Trench, Georgia. AU - Australian Ovarian Cancer Study Group, Ovarian Cancer Study Group. AU - Dale, Laura C.. AU - Lambrechts, Diether. AU - Amant, Frederic. AU - Despierre, Evelyn. AU - Vergote, Ignace. AU - Gayther, Simon A.. AU - Gentry-Maharaj, Aleksandra. AU - Menon, Usha. AU - Chang-Claude, Jenny. AU - Wang-Gohrke, Shan. AU - Anton-Culver, Hoda. AU - Ziogas, Argyrios. AU - Dörk, Thilo. AU - Dürst, Matthias. AU - Antonenkova, Natalia. AU - Bogdanova, Natalia. AU - Brown, Robert. AU - Flanagan, James M.. AU - Kaye, Stanley B.. AU - Paul, James. AU - Bützow, Ralf. AU - Nevanlinna, Heli. AU - Campbell, ...
Cell lines and culture. The derivation, source, and propagation of human epithelial ovarian cancer cell lines, such as cisplatin-sensitive (A2780-PAR) and platinum-resistant (A2780-CP20 and RMG2) epithelial ovarian cancer cell lines, were maintained as previously described (30). The A2780-CP20 cell line was developed by sequential exposure of the A2780 cell line to increasing concentrations of cisplatin. All experiments were done with 70% to 80% confluent cultures.. ATP7A and ATP7B gene silencing by siRNA. siRNA constructs targeted to ATP7A and ATP7B were designed and purchased from Qiagen. The target sequences were 5′-CTGGACCGGATTGTTAATTAT-3′ (for ATP7A) and 5′-CCAATTGATATTGAGCGGTTA-3′ (for ATP7B). In vitro transient transfection was done as described previously (28). Briefly, cells were transfected with ATP7A- and/or ATP7B-specific or scrambled (control) siRNA using RNAiFect reagent (Qiagen). At selected time intervals, cells were harvested to measure mRNA and protein levels of ATP7B ...
Xu, J., et al. Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues. The International Journal of Biochemistry & Cell Biology. S1357-2725(18)30258-9. 10/12/2018.. We identified 634 differentially expressed peptides, 508 of these peptides were highly abundant in serous ovarian cancer tissues, a result consistent with higher protease activity in ovarian cancer patients. The difference in preferred cleavage sites between the serous ovarian cancer tissues and normal ovarian epithelium indicates the characteristic peptidome of ovarian cancer and the nature of cancer-associated protease activity. Interestingly, KEGG pathway analysis of the peptide precursors indicated that the differentially regulated pathways in ovarian cancer are highly consistent with the pathways discovered in other cancers. Besides, we found that a proportion of the differentially expressed peptides are similar to the known immune-regulatory peptides and anti-bacterial peptides. Then we further ...
Vectors based on adenoviruses have been designed as targeted anti-cancer therapeutics that showed promising results in pre-clinical applications. In clinical trials, these oncolytic adenoviruses have generally been proved safe in patients, but have fallen short of their expected therapeutic value. In this thesis the susceptibility of primary ovarian cancer cells to oncolytic adenoviruses was studied in order to identify cellular mechanisms that confer resistance to virotherapy. Using gene expression profiling of cancer cells either resistant or susceptible to viral oncolysis, it was discovered that the epithelial phenotype of ovarian cancer represents a barrier to infection by commonly used oncolytic adenoviruses targeted to coxsackie- and adenovirus receptor (CAR) or CD46. Accessibility to viral receptors was critically linked to depolarization and the loss of tight and adherens junctions, both hallmarks of epithelial-mesenchymal transition (EMT). Importantly, tumors in situ as well as ...
We have previously demonstrated that Kruppel-like factor 8 (KLF8) participates in oncogenic transformation of mouse fibroblasts and is highly overexpressed in human ovarian cancer. In this work, we first correlated KLF8 overexpression with the aggressiveness of ovarian patient tumors and then tested if KLF8 could transform human ovarian epithelial cells. Using the immortalized non-tumorigenic human ovarian surface epithelial cell line T80 and retroviral infection, we generated cell lines that constitutively overexpress KLF8 alone or its combination with the known ovarian oncogenes c-Myc, Stat3c and/or Akt and examined the cell lines for anchorage-independent growth and tumorigenesis. The soft agar clonogenic assay showed that T80/KLF8 cells formed significantly more colonies than the mock cells. Interestingly, the cells expressing both KLF8 and c-Myc formed the largest amounts of colonies, greater than the sum of colonies formed by the cells expressing KLF8 and c-Myc alone. These results suggested that
Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
DISEASE CHARACTERISTICS: Histologically confirmed stage III ovarian epithelial cancer or primary peritoneal carcinoma of one of the following cell types: Serous adenocarcinoma Mucinous adenocarcinoma Clear-cell adenocarcinoma Endometrioid Adenocarcinoma (not otherwise specified) Undifferentiated carcinoma Transitional cell Malignant Brenners tumor Mixed epithelial carcinoma No borderline tumor (tumor of low malignant potential) Underwent prior standard initial cytoreductive surgery within the past 6 weeks Optimally resected disease with no residual site of disease more than 1 cm in greatest dimension Removal of all disease extending beyond the reproductive tract Total hysterectomy and bilateral salpingo-oopherectomy at cytoreductive surgery or in the past. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no ...
A DNA repair pathway-focused score has the potential to help determine if first-line platinum based chemotherapy can benefit advanced-stage ovarian cancer patients, according to a study published April 13 in the Journal of the National Cancer Institute.. Most ovarian cancer patients are diagnosed with advanced disease (stages III and IV). They undergo surgery to remove as much tumor as possible, and then undergo platinum-based chemotherapy. But tools to predict response to platinum-based chemotherapy in ovarian cancer patients have been inadequate.. In order to determine if a DNA repair pathway-focused score could help predict outcomes for ovarian cancer patients treated with platinum-based chemotherapy, Josephine Kang, M.D., Ph.D., of the Department of Radiation Oncology at Dana Farber Cancer Institute, and colleagues gathered gene expression data from The Cancer Genome Atlas (TCGA) database for patients with advanced stage ovarian cancer, and established a molecular score by looking at the ...
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum ...
The receptor tyrosine kinase AXL is thought to play a role in metastasis; however, the therapeutic efficacy of an AXL-targeting agent remains largely untested in metastatic disease. In this study, we defined AXL as a therapeutic target for metastatic ovarian cancer. AXL is primarily expressed in metastases and advanced-stage human ovarian tumors but not in normal ovarian epithelium. Genetic inhibition of AXL in human metastatic ovarian tumor cells is sufficient to prevent the initiation of metastatic disease in vivo. Mechanistically, inhibition of AXL signaling in animals with metastatic disease results in decreased invasion and matrix metalloproteinase activity. Most importantly, soluble human AXL receptors that imposed a specific blockade of the GAS6/AXL pathway had a profound inhibitory effect on progression of established metastatic ovarian cancer without normal tissue toxicity. These results offer the first genetic validation of GAS6/AXL targeting as an effective strategy for inhibition of
TY - JOUR. T1 - Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer. AU - Sakuma, Michiko. AU - Akahira, Jun Ichi. AU - Suzuki, Takashi. AU - Inoue, Satoshi. AU - Ito, Kiyoshi. AU - Moriya, Takuya. AU - Sasano, Hironobu. AU - Okamura, Kunihiro. AU - Yaegashi, Nobuo. N1 - Funding Information: This work was supported in part by a grant-in-aid for Scientific Research from the Ministry of Health and Welfare, a grant-in-aid from the Ministry of Education, Science and Culture, a grant-in-aid from Kurokawa Cancer Research Foundation, a grant-in-aid from Japan Gynecologic Oncology Group (JGOG) and the 21st Century Center of Excellence (COE) Program Special Research Grant from the Ministry of Education Science, Sports and Culture.. PY - 2005/12. Y1 - 2005/12. N2 - Objective. The estrogen-responsive ring finger protein (Efp) gene, one of estrogen receptor (ER) target genes, is considered to be essential for estrogen-dependent cell ...
TY - JOUR. T1 - A single nucleotide polymorphism in catalase is strongly associated with ovarian cancer survival. AU - Belotte, Jimmy. AU - Fletcher, Nicole M.. AU - Saed, Mohammed G.. AU - Abusamaan, Mohammed S.. AU - Dyson, Gregory. AU - Diamond, Michael P.. AU - Saed, Ghassan M.. PY - 2015/8/24. Y1 - 2015/8/24. N2 - Ovarian cancer is the deadliest of all gynecologic cancers. Recent evidence demonstrates an association between enzymatic activity altering single nucleotide polymorphisms (SNP) with human cancer susceptibility. We sought to evaluate the association of SNPs in key oxidant and antioxidant enzymes with increased risk and survival in epithelial ovarian cancer. Individuals (n = 143) recruited were divided into controls, (n = 94): healthy volunteers, (n = 18), high-risk BRCA1/2 negative (n = 53), high-risk BRCA1/2 positive (n = 23) and ovarian cancer cases (n = 49). DNA was subjected to TaqMan SNP genotype analysis for selected oxidant and antioxidant enzymes. Of the seven selected SNP ...
Younger women with early-stage ovarian cancer can keep the healthy ovary and uterus, according to the September 15, 2009, issue of Cancer....
MD Andersons physicians specialize in treating all types of ovarian cancer. Learn more about ovarian cancer treatment, surgery, chemotherapy and other options.
We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in
Epithelial ovarian cancer (EOC) is highly lethal gynecological cancer. Forkhead Box Protein C2 (FOXC2) promotes occurrence and development of various malignant tumors. The present study is aimed at exploring the correlation between the polymorphism of FOXC2 and epithelial ovarian cancer susceptibility in Chinese Han population. A case-control design was used to verify the association between FOXC2 polymorphisms and epithelial ovarian cancer. The genotyping was performed using Taqman® SNP Genotyping kit by qRT-PCR. The genetic variants including rs3751794 C | T, rs1035550 A | G, rs4843163 C | G and rs4843396 C | T in FOXC2 gene were analyzed. The strength of the associations was detected using odds ratios and 95% confidence intervals. Stratification analyses showed the association between the FOXC2 gene polymorphisms rs3751794 C | T, rs4843163 C | G and rs4843396 C | T with epithelial ovarian cancer susceptibility in terms of age, metastasis status, clinical stage, pathological grade, pregnant times,
The role of estrogen in the growth and survival of ovarian cancer cells is controversial. In this study, we investigated the changes in cell-cycle regulatory proteins in ovarian cancer cell lines after estrogen treatment to explore the role of estrog
Background Glycogen synthase kinase-3 (GSK-3) is a multifunctional serine/threonine kinase that has an important function in cancers tumorigenesis and development. at both mRNA and proteins levels. Conclusion Used together, our outcomes demonstrate the fact that GSK-3 inhibitor AZD1080 suppresses ovarian cancers development and for that reason may indicate a fresh path for ovarian cancers treatment. strong course=kwd-title Keywords: ovarian cancers, GSK-3 inhibitor, AZD1080, tumorigenesis, development Introduction Ovarian cancers may be the third most common feminine reproductive system cancer tumor. The ovarian cancers mortality rate may be the highest from the gynecological malignancies because of the insufficient effective early diagnostic strategies, its chemotherapy level of resistance, and its capability to metastasize and recurrence. The 5-calendar year survival rate is certainly 30%, rendering it as a significant threat to medical and lives of females.1,2 Ovarian cancers has many ...
Cancer Monthly. Ovarian Cancer treatments. Chemotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States. Compare therapy differences, longest survival rates, toxicity, side effects, hospitals.
Cancer Monthly. Ovarian Cancer treatments. Chemotherapy. Sloan-Kettering Cancer Center, New York, United States. Compare therapy differences, longest survival rates, toxicity, side effects, hospitals.
Ovarian cancer is a type of cancer that begins in a womens ovaries. Women have two ovaries that produce eggs as well as the hormones estrogen and progesterone. Ovarian cancer can be hard to diagnose because early-stages of ovarian cancer rarely cause any symptoms and advanced-stage ovarian cancer may cause few and nonspecific symptoms. The symptoms of ovarian cancer may include abdominal bloating, quickly feeling full when eating, weight loss, cramping in the lower stomach, changes in bowel habits, and a frequent need to urinate.. The cause of ovarian cancer is unclear. In general, cancer is caused by genetic mutations that turn normal cells into abnormal cancer cells that quickly multiply, forming a mass (tumor). The type of cell where the cancer begins determines the type of ovarian cancer. These types included epithelial tumor, stromal tumor, and germ cell tumor. Certain factors may increase your risk of ovarian cancer. These include age (most common in women ages 50 to 60), estrogen hormone ...
The distribution of genotypes for Arg399Gln XRCC1 polymorphism in ovarian cancers vs. controls was: 58.0% vs. 38.5% for Arg/Arg, 32.0% vs. 26.9% for Arg/Gln, and 10.0% vs. 34.6% for Gln/Gln genotype, respectively. We found that XRCC1 Arg allele is associated with ovarian cancer risk (OR= 2.635 for Arg vs. Gln with 95% CI of 1.526 to 4.550). The Arg allele exerts its effect on increased risk for ovarian cancer development in dominant model (Arg/Arg plus Arg/Gln vs. Gln/Gln) with OR (and 95 % CI) of 4.765 (1.692 to 13.414) as well as in recessive model (Arg/Arg vs. Arg/Gln plus Gln/Gln) with OR (and 95 % CI) of 2.210 (1.072 to 4.555). ...
At Minnesota Oncology, ovarian cancer treatment options are individualized according to the patients type and stage of cancer and also other factors.
Table of Contents. 1 Market Overview. 1.1 Ovarian Cancer Treatment Drugs Introduction. 1.2 Market Analysis by Type. 1.2.1 Platinum Anticancer Drugs. 1.2.2 Fluoropyrimidines. 1.2.3 Anthracycline Antibiotics. 1.2.4 Therapertic Antibody. 1.2.5 Small Molecules Drug. 1.2.6 Aromatase Inhibitors (Targeted Therapy Drug). 1.2.7 Anti-estrogens. 1.2.8 Aromatase Inhibitors (Endocrine Therapy Drug). 1.3 Market Analysis by Applications. 1.3.1 Hospital. 1.3.2 Clinic. 1.3.3 Drugstore. 1.4 Market Analysis by Regions. 1.4.1 North America (United States, Canada and Mexico). 1.4.1.1 United States Market States and Outlook (2013-2023). 1.4.1.2 Canada Market States and Outlook (2013-2023). 1.4.1.3 Mexico Market States and Outlook (2013-2023). 1.4.2 Europe (Germany, France, UK, Russia and Italy). 1.4.2.1 Germany Market States and Outlook (2013-2023). 1.4.2.2 France Market States and Outlook (2013-2023). 1.4.2.3 UK Market States and Outlook (2013-2023). 1.4.2.4 Russia Market States and Outlook (2013-2023). 1.4.2.5 ...
This study focuses on Chinas Ovarian Cancer Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed Chinas society and economy. China is one of the worlds major producers for industrial and consumer products. Far outpacing other economies in the world, China is the worlds fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market ...
TY - JOUR. T1 - Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. AU - Yemelyanova, A. V.. AU - Cosin, J. A.. AU - Bidus, M. A.. AU - Boice, C. R.. AU - Seidman, J. D.. PY - 2008/5/1. Y1 - 2008/5/1. N2 - The progression of ovarian carcinoma from stage I when it is confined to the ovaries and curable to disseminated abdominal disease, which is usually fatal, is poorly understood. An accurate understanding of this process is fundamental to designing, testing, and implementing an effective screening program for ovarian cancer. Pathologic features of the primary ovarian tumors in 41 FIGO stage I ovarian carcinomas were compared with those in 40 stage III carcinomas. The primary ovarian tumors in stage I cases, when compared with stage III, respectively, were significantly larger (15.4 versus 9.8 cm), were less frequently bilateral (12% versus 75%), more frequently contained a noninvasive component (88% versus 30%), had a higher proportion of a ...
The aim of the study was to investigate long-term trends in the incidence of borderline tumors and ovarian cancer in Sweden during 1960-2005, based on data from the population-based Swedish Cancer Register. We identified 6,288 patients with borderline ovarian tumors and a total of 34,977 cases of ovarian cancer during the study period. The age-standardized incidence of borderline ovarian tumors increased from 1.0 to 5.3 per 100,000 women-years from 1960-1964 to 2000-2005 and the incidence of ovarian cancer increased from 16.4 to 19.7 per 100,000 women-years from 1960-1964 to 1980-1989 and then declined to 16.6 per 100,000 women-years to the period 2000-2005. Borderline ovarian tumors comprised 15% of all primary ovarian neoplasms and the proportion increased from 8.3 to 23.6% during the study period. The median age at diagnosis for patients with borderline ovarian tumors and ovarian cancer was 55.2 and 61.6 years, respectively. In women younger than 40 years, 34% of all primary ovarian ...
Metastatic Ovarian Cancer-Pipeline Review, H2 2015. Summary. Global Markets Directs, Metastatic Ovarian Cancer-Pipeline Review, H2 2015, provides an overview of the Metastatic Ovarian Cancers therapeutic pipeline.. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC ...
TY - JOUR. T1 - Role of CSF-1 in progression of epithelial ovarian cancer. AU - Chambers, Setsuko K. PY - 2009. Y1 - 2009. N2 - Despite the dismal outcome seen in the majority of epithelial ovarian cancer patients, there is ongoing progress in understanding the disease at a molecular level. Elucidation of pathways underlying disease progression and metastasis of ovarian cancer is key to development of targeted therapeutics. It is only in this way that therapeutic potential can be translated to reality. Here, we describe the evidence to date for the role of CSF-1/c-fms signaling in ovarian cancer invasiveness and metastasis, including the recent understanding of how CSF-1/c-fms expression is regulated with identification of significant post-transcriptional regulators.. AB - Despite the dismal outcome seen in the majority of epithelial ovarian cancer patients, there is ongoing progress in understanding the disease at a molecular level. Elucidation of pathways underlying disease progression and ...
The biology of ovarian carcinoma differs from that of hematogenously metastasizing tumors because ovarian cancer cells primarily disseminate within the peritoneal cavity and are only superficially invasive. However, since the rapidly proliferating tumors compress visceral organs and are only temporarily chemosensitive, ovarian carcinoma is a deadly disease, with a cure rate of only 30%. There are a number of genetic and epigenetic changes that lead to ovarian carcinoma cell transformation. Ovarian carcinoma could originate from any of three potential sites: the surfaces of the ovary, the fallopian tube, or the mesothelium-lined peritoneal cavity. Ovarian cacinoma tumorigenesis then either progresses along a stepwise mutation process from a slow growing borderline tumor to a well-differentiated carcinoma (type I) or involves a genetically unstable high-grade serous carcinoma that metastasizes rapidly (type II). During initial tumorigenesis, ovarian carcinoma cells undergo an ...
(HealthDay)-Operative outcomes of laparoscopic approach in patients with early-stage ovarian cancer may be comparable with those of laparotomy, according to a meta-analysis published in the July issue of the American Journal ...
TY - JOUR. T1 - Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role. T2 - A Southwest Oncology Group ancillary study. AU - Hawes, Debra. AU - Liu, P. Y.. AU - Muggia, Franco M.. AU - Wilczynski, Sharon. AU - Cote, Richard. AU - Felix, Juan. AU - Terada, Keith. AU - Belt, Robert J.. AU - Alberts, David S. PY - 2002. Y1 - 2002. N2 - Objective. The objective of this study was to verify the correlation between p53 immunostaining at initial diagnosis and at positive reassessment after completing platinum-based chemotherapy and to assess prognostic differences between patients whose tumors display positive immunostaining versus those that have negative immunostaining at such reassessment. Methods. This study made use of samples from patients entered into a prospective randomized study of the Southwest Oncology Group (SWOG 8835) that treated patients with minimal residual disease at second-look laparotomy with ...
Title:PARP Inhibitors in Epithelial Ovarian Cancer. VOLUME: 13 ISSUE: 2. Author(s):Kristin N. Taylor and Ramez N. Eskander*. Affiliation:Rebecca and John Moores Cancer Center, Department of Reproductive Medicine, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, Rebecca and John Moores Cancer Center, Department of Reproductive Medicine, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA. Keywords:BRCA mutation, homologous recombination deficiency, PARP inhibitor, poly (ADP-ribose) polymerase, ovarian cancer, synthetic lethality.. Abstract:Background: Ovarian cancer remains the most common lethal gynecologic malignancy. The therapeutic gains with the use of traditional cytotoxic chemotherapy in advanced stage disease remain limited, reflecting the need for novel therapies. Poly(ADP-ribose) polymerase (PARP) inhibitors have recently demonstrated a significant therapeutic effect in patients with recurrent, high grade serous ovarian ...
TY - JOUR. T1 - Ovarian cancer detection by DNA methylation in cervical scrapings. AU - Wu, Tzu I.. AU - Huang, Rui Lan. AU - Su, Po Hsuan. AU - Mao, Shih Peng. AU - Wu, Chen Hsuan. AU - Lai, Hung Cheng. PY - 2019/11/27. Y1 - 2019/11/27. N2 - Background: Ovarian cancer (OC) is the most lethal gynecological cancer, worldwide, largely due to its vague and nonspecific early stage symptoms, resulting in most tumors being found at advanced stages. Moreover, due to its relative rarity, there are currently no satisfactory methods for OC screening, which remains a controversial and cost-prohibitive issue. Here, we demonstrate that Papanicolaou test (Pap test) cervical scrapings, instead of blood, can reveal genetic/epigenetic information for OC detection, using specific and sensitive DNA methylation biomarkers. Results: We analyzed the methylomes of tissues (50 OC tissues versus 6 normal ovarian epithelia) and cervical scrapings (5 OC patients versus 10 normal controls), and integrated public methylomic ...
MicroRNAs (miRNAs) are small noncoding RNAs that have important roles in gene regulation. We have previously reported that activin receptor-like kinase 7 (ALK7) and its ligand, Nodal, induce apoptosis in human epithelial ovarian cancer cells. In this study, we examined the regulation of ALK7 by miRNAs and demonstrate that miR-376c targets ALK7. Ectopic expression of miR-376c significantly increased cell proliferation and survival, enhanced spheroid formation and blocked Nodal-induced apoptosis. Interestingly, overexpression of miR-376c blocked cisplatin-induced cell death, whereas anti-miR-376c enhanced the effect of cisplatin. These effects of miR-376c were partially compensated by the overexpression of ALK7. Moreover, in serous carcinoma samples taken from ovarian cancer patients who responded well to chemotherapy, strong ALK7 staining and low miR-376c expression was detected. By contrast, ALK7 expression was weak and miR-376c levels were high in samples from patients who responded poorly to ...
In this study a new low-grade serous ovarian carcinoma cell line, named as CAISMOV24, was characterized in terms of its in vitro cell growth, production of soluble biomarkers and expression of cell surface molecules. Additionally, CAISMOV24 was molecularly characterized and compared to its primary malignant cells for genomic alterations. In vitro models of well-characterized low-grade serous ovarian cell lines are currently limited in the literature. CAISMOV24 resulted from the in vitro spontaneous immortalization of primary malignant cells from ascites that was associated with a low-grade serous ovarian carcinoma. Although malignant cells of ovarian neoplasia from either tumor tissue or ascites can be cultivated in vitro for a limited period, only a minority of the primary cell cultures may become cell lines [14]. Spontaneous immortalization of primary cultures of malignant cells is an event occurring at a very low frequency. As an example, ODonnell et al. [11] reported the occurrence of only ...
Stage three ovarian cancer survival rate is somewhat high. Stage 3 is a serious level of ovarian cancer but life expectancy is still considered high. Abo
Research highlights: {yields} PPAR{gamma} ligands increased the rate of apoptosis and inhibition of proliferation in ovarian cancer cells. {yields} PPAR{gamma} ligands induced p63 and p73 expression, but not p53. {yields} p63 and p73 leads to an increase in p21 expression and apoptosis in ovarian cancer cells with treatment PPAR{gamma} ligands. {yields} These findings suggest that PPAR{gamma} ligands suppressed growth of ovarian cancer cells through upregulation of p63 and p73. -- Abstract: Peroxisome proliferator-activated receptor gamma (PPAR{gamma}) agonists, including thiazolidinediones (TZDs), can induce anti-proliferation, differentiation, and apoptosis in various cancer cell types. This study investigated the mechanism of the anticancer effect of TZDs on human ovarian cancer. Six human ovarian cancer cell lines (NIH:OVCAR3, SKOV3, SNU-251, SNU-8, SNU-840, and 2774) were treated with the TZD, which induced dose-dependent inhibition of cell growth. Additionally, these cell lines exhibited ...
Bisphenol A (BPA) is one of the most prevalent chemicals in many products used on a daily basis, making human exposure to it incredibly pervasive and raising concerns about its health consequences. One area of research focus has been the role of BPA exposure in promoting the development of ovarian cancer; however, the doses used in most of previous studies are relatively high and most likely exceed physiologically relevant levels. At the same time, few studies have described potential mechanisms underlying the link between BPA and increased cancer risk. To address these concerns, the authors investigated the mechanism(s) by which low concentrations of BPA promote proliferation and energy metabolism in the human ovarian cancer cell line OVCAR-3. The results showed that even sub-toxic BPA concentrations not only drove increased OVCAR-3 cell proliferation but also promoted glycolysis-based metabolism, as evidenced by elevated cell viability, accelerated cell proliferation, increased levels of ...
Ovarian Epithelial Cancer Treatment India, Ovarian Epithelial Cancer Treatment Cost In India Info On Cost Ovarian Epithelial Cancer Treatment Mumbai Delhi Bangalore India, Ovarian Epithelial Cancer Treatment Hospitals Center Mumbai India, Ovarian Epithelial Cancer Treatment Surgeon India
TY - JOUR. T1 - Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer. AU - Bogani, Giorgio. AU - Rossetti, Diego. AU - Ditto, Antonino. AU - Martinelli, Fabio. AU - Chiappa, Valentina. AU - Mosca, Lavinia. AU - Leone Roberti Maggiore, Umberto. AU - Ferla, Stefano. AU - Lorusso, Domenica. AU - Raspagliesi, Francesco. N1 - Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.. PY - 2018/9. Y1 - 2018/9. N2 - OBJECTIVE: Accumulating evidence support that complete cytoreduction (CC) at the time of secondary cytoreductive surgery (SCS) improves survival in patients affected by recurrent ovarian cancer (ROC). Here, we aimed to determine whether artificial intelligence (AI) might be useful in weighting the importance of clinical variables predicting CC and survival.METHODS: This is a retrospective study evaluating 194 patients having SCS for ROC. Using ...
TY - JOUR. T1 - Methiothepin suppresses human ovarian cancer cell growth by repressing mitochondrion-mediated metabolism and inhibiting angiogenesis in vivo. AU - Lee, Jin Young. AU - Yang, Changwon. AU - Lim, Whasun. AU - Song, Gwonhwa. N1 - Funding Information: This research was supported by the NRF of Korea grant funded by the Ministry of Science and ICT (2018R1C1B6009048). Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.. PY - 2020/7. Y1 - 2020/7. N2 - Ovarian cancer is the fifth leading cause of cancer-related deaths in women. Despite treatment, most patients experience relapse and the 5-year survival rate of ovarian cancer is less than 50%. Serotonin has cell growth-promoting functions in a variety of carcinomas, but the effect of serotonin receptor antagonists on ovarian cancer cells is unknown. In this study, it was confirmed that methiothepin, a serotonin receptor antagonist, suppresses the viability of, and induces apoptosis in, ovarian cancer cells. ...
Mucinous epithelial ovarian cancers are clinically and morphologically distinct through the various other histopathologic subtypes of ovarian cancer. signaling pathways. Immunohistochemistry of archived ovarian specimens showed significant overexpression of eight of the nine target antigens in mucinous ovarian tumor tissues, suggesting that plasma autoantibodies from mucinous ovarian cancer patients might have heightened reactivities with epitopes presented by these overexpressed antigens. Autoantibody profiling may have an unexpected power in uncovering key signaling pathways that are dysregulated in the system of interest. or mutations, have frequent mutations and modest ratio between the serum markers CA125 and carcinoembryonic antigen CEA (5). Molecular and pathologic studies also support a progression model for the development of mucinous ovarian tumors (6). Transitions between benign and malignant areas are seen in 80% of malignant mucinous adenocarcinomas. Identical mutations are ...
GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020 Jan 11;:109539 Authors: El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G Abstract High-grade serous ovarian carcinoma (HGSOC) is the mos...
TY - JOUR. T1 - Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors. T2 - A novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. AU - Wang, Jun. AU - Lin, Lynne. AU - Parkash, Vinita. AU - Schwartz, Peter E.. AU - Lauchlan, Stuart C.. AU - Zheng, Wenxin. PY - 2003/1/20. Y1 - 2003/1/20. N2 - The role of FSHR expression in ovarian cancer development is not clear. We examined quantitative expression of FSHR in different types of OET, presumed precursor lesions and peritoneal implants and further discussed FSH as a key growth-promotion factor for the process of ovarian epithelial tumorigenesis. Thirty-five primary OET specimens, including 5 serous cystadenomas, 4 papillary serous cystadenomas, 9 SBTs and 17 serous carcinomas, were examined for quantitative FSHR expression. Ten paired samples (3 benign cystadenomas, 5 SBTs and 2 carcinomas) were obtained from several morphologically different areas, including ...
TY - JOUR. T1 - Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells. T2 - Cytoplasmic sequestration of CDK2 by p27. AU - Itamochi, Hiroaki. AU - Yoshida, Tomokazu. AU - Walker, Cheryl Lyn. AU - Bartholomeusz, Chandra. AU - Aoki, Daisuke. AU - Ishihara, Hideki. AU - Suzuki, Nao. AU - Kigawa, Junzo. AU - Terakawa, Naoki. AU - Ueno, Naoto T.. PY - 2011/9. Y1 - 2011/9. N2 - Objective: Ovarian clear cell carcinoma (CCC) carries a poor prognosis because of its insensitivity to chemotherapy. We previously found an association between reduced proliferation of CCC and chemoresistance; here we investigated the mechanism of the reduced proliferation. Methods: We assessed cell cycle function by measuring the activity of cyclin-dependent kinases (CDKs) and the protein expression of cyclins, the CDK inhibitors, and p53 in 22 ovarian cancer cell lines and 60 human ovarian cancer specimens. We examined the cellular location of p27, p27 phosphorylated at threonine 157 (p27Thr157), and ...
TY - JOUR. T1 - Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds. AU - Casey, Murray J.. AU - Bewtra, Chhanda. AU - Lynch, Henry T.. AU - Snyder, Carrie L.. AU - Stacey, Mark. PY - 2015/5/7. Y1 - 2015/5/7. N2 - Objective The aim of this study was to categorize and report endometrial cancers in mutation carriers from hereditary breast ovarian cancer families. Methods Our Hereditary Cancer Registry was searched for gynecologic and peritoneal cancers linked to mutations in BRCA1 or BRCA2. Invasive cancers were registered in 101 mutation carriers with complete pathology reports. Efforts were made to secure diagnostic surgical pathology tissues for review. All records and available diagnostic slides were meticulously studied, and primary cancers were classified. Findings Eight malignancies were classified as primary endometrial cancers. Five of these were low- or intermediate-grade endometrioid carcinomas, and 3 were pure serous carcinomas or contained ...
The expression of mismatch repair proteins hMSH2 and hMLH1 was investigated in human ovarian cancer cell lines and in biopsies of ovarian carcinomas obtained from 20 patients undergoing surgical operation. By Western blotting analysis hMSH2 protein was detected in all the tumor samples analyzed and in eight out of nine human ovarian cancer cell lines, while hMLH1 was undetectable in four out of 20 ovarian tumors and in five out of nine human ovarian cancer cell lines analyzed. The possible presence of frameshift mutations in the BAX gene, which contains a sequence of eight contiguous guanines in its third exon, was tested in all the samples. All the cell lines presented the normal alleles for the BAX gene while only in one of the tumor samples a heterozygous frameshift mutation was found. The frameshift mutation was associated to a low, almost undetectable, level of BAX protein which was instead present at much higher levels in all the other samples investigated. The results indicate that ...
Krukenbergs tumours are metastatic tumours of the ovary. The colon and stomach are the most common primary tumour sites. Breast, lung, and pancreas are the other sites of metastasis. These tumours constitute 5-10% of ovarian neoplasms.. The differential diagnosis from a primary ovarian tumour is very important for therapeutic approach. Krukenbergs tumours are bilateral in 60-80% of cases. Therefore whenever bilateral ovarian involvement is detected, a search for a primary site, especially in the gastrointestinal system, should be carried out. In contrast to primary ovarian tumours, the ovaries keep their shape in Krukenbergs tumour. Some other radiological findings give important clues. Early in the development of these tumours, the solid component is most prominent, as seen in this case. At US Krukenberg tumor typically present as bilateral, solid ovarian masses, with clear well defined margins. An irregular hyperechoic solid pattern and moth eaten like cyst formation are also ...
Ascites formation is often observed in ovarian cancer patients. Vascular permeability factor (VPF) may induce ascites formation. We established an animal model of ascites formation and re-accumulation by i.p. transplantation of a human ovarian adenocarcinoma cell line, NOS2, into nude mice. The form …
Curcumin is a natural molecule with proved anticancer efficacy on several human cancer cell lines. However, its clinical application has been limited due to its poor bioavailability. Nanocarrier-based drug delivery approaches could make curcumin dispersible in aqueous media, thus overtaking the limits of its low solubility. The aim of this study was to increase the bioavailability and the antitumoral activity of curcumin, by entrapping it into nanostructured lipid carriers (NLCs). For this purpose here we describe the preparation and characterization of three kinds of curcumin-loaded NLCs. The nanosystems allowed the achievement of a controlled release of curcumin, the amounts of curcumin released after 24 h from Compritol-Captex, Compritol-Miglyol, and Compritol NLCs being, respectively, equal to 33, 28, and 18% w/w on the total entrapped curcumin. Considering the slower curcumin release profile, Compritol NLCs were chosen to perform successive in vitro studies on ovarian cancer cell lines. The ...
Chemokine receptor-ligand interactions are important to support functioning of both normal and pathologic cells. The expression and function of chemokine receptors in epithelial ovarian carcinoma (EOC) is largely unknown. Here, we report that the lymphotactin receptor (XCR1) was expressed in primary and metastatic human epithelial ovarian carcinoma (EOC) specimens and cell lines. In contrast, expression of XCR1 was not detected in the normal ovary or in human normal ovarian surface epithelial cells. Our data indicate that XCL1 and XCL2 are either present in the malignant ascites or expressed by the ovarian carcinoma cells. The addition of lymphotactin (XCL1 and XCL2) stimulated migration and proliferation of XCR1-positive cells. Reduction of XCR1 expression in ovarian carcinoma cell line SKOV-3 resulted in abrogated diaphragm and peritoneal wall tumor formation and in reduced frequency of colonic, splenetic, and liver nodules in an in vivo xenograft mouse model. Taken together, our data suggest ...
Combination drug therapy appears a promising approach to overcome drug resistance and reduce drug-related toxicities in ovarian cancer treatments. In this in vitro study, we evaluated the antitumor efficacy of cisplatin in combination with Bithionol (BT) against a panel of ovarian cancer cell lines with special focus on cisplatin-sensitive and cisplatin-resistant cell lines. The primary objectives of this study are to determine the nature of the interactions between BT and cisplatin and to understand the mechanism(s) of action of BT-cisplatin combination. The cytotoxic effects of drugs either alone or in combination were evaluated using presto-blue assay. Cellular reactive oxygen species were measured by flow cytometry. Immunoblot analysis was carried out to investigate changes in levels of cleaved PARP, XIAP, bcl-2, bcl-xL, p21 and p27. Luminescent and colorimetric assays were used to test caspases 3/7 and ATX activity. The efficacy of the BT-cisplatin combination depends upon the cell type and
The expression of mRNA for the epidermal growth factor (EGF) receptor, EGF and transforming growth factor alpha (TGF-alpha) was determined in 76 malignant, six borderline and 15 benign primary ovarian tumours using the reverse transcriptase-polymerase chain reaction and related to clinical and pathological parameters. Of the malignant tumours, 70% (53/76) expressed EGF receptor mRNA, 31% (23/75) expressed EGF mRNA and 35% (26/75) expressed TGF-alpha mRNA. For the borderline tumours, four of six (67%) expressed EGF receptor mRNA, 1/6 (17%) expressed TGF-alpha mRNA and none expressed EGF mRNA. Finally, 33% (5/15) of the benign tumours expressed EGF receptor mRNA, whereas 40% (6/15) expressed EGF mRNA and 7% (1/15) expressed TGF-alpha mRNA. The presence of the EGF receptor in malignant tumours was associated with that of TGF-alpha (P = 0.0015) but not with EGF (P = 1.00), whereas there was no relationship between the presence of EGF and TGF-alpha (P = 1.00). EGF receptor mRNA expression was significantly
TY - JOUR. T1 - Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role. T2 - A Southwest Oncology Group ancillary study. AU - Hawes, Debra. AU - Liu, P. Y.. AU - Muggia, Franco M.. AU - Wilczynski, Sharon. AU - Cote, Richard J. AU - Felix, Juan. AU - Terada, Keith. AU - Belt, Robert J.. AU - Alberts, David S.. PY - 2002/12/1. Y1 - 2002/12/1. N2 - Objective. The objective of this study was to verify the correlation between p53 immunostaining at initial diagnosis and at positive reassessment after completing platinum-based chemotherapy and to assess prognostic differences between patients whose tumors display positive immunostaining versus those that have negative immunostaining at such reassessment. Methods. This study made use of samples from patients entered into a prospective randomized study of the Southwest Oncology Group (SWOG 8835) that treated patients with minimal residual disease at second-look ...
Abstract Hyperthermic intraperitoneal chemotherapy (HIPEC) has shown promise in the treatment of ovarian carcinosis. Despite its efficiency for the treatment of peritoneal carcinosis from digestive tract neoplasia, it has failed to demonstrate significant benefit in ovarian cancers. It is therefore essential to understand the mechanism underlying the resistance to HIPEC in ovarian cancers. Mesenchymal Stem Cells (MSC) play an important role in the development of ovarian cancer metastasis and resistance to treatments. A recent study suggests that MSCs may be cytotoxic for cancer cells upon heat shock. In contrast, we describe the protective role of MSC against hyperthermia. Using cytokine arrays we determined that tumor associated MSC (TAMC) secrete pro-tumoral cytokines. We studied the effect of hyperthermia in co-culture setting of TAMC or bone marrow derived-MSC (BM-MSC) associated with ovarian cancer cell lines (SKOV3 and CaOV3) with polyvariate flow cytometry. We demonstrate that hyperthermia does
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer
TY - JOUR. T1 - Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. AU - Pearce, C. L.. AU - Near, A. M.. AU - Van Den Berg, D. J.. AU - Ramus, S. J.. AU - Gentry-Maharaj, A.. AU - Menon, U.. AU - Gayther, S. A.. AU - Anderson, A. R.. AU - Edlund, C. K.. AU - Wu, A. H.. AU - Chen, X.. AU - Beesley, J.. AU - Webb, P. M.. AU - Holt, S. K.. AU - Chen, C.. AU - Doherty, J. A.. AU - Rossing, M. A.. AU - Whittemore, A. S.. AU - McGuire, V.. AU - DiCioccio, R. A.. AU - Goodman, M. T.. AU - Lurie, G.. AU - Carney, M. E.. AU - Wilkens, L. R.. AU - Ness, R. B.. AU - Moysich, K. B.. AU - Edwards, R.. AU - Jennison, E.. AU - Kjaer, S. K.. AU - Hogdall, E.. AU - Hogdall, C. K.. AU - Goode, E. L.. AU - Sellers, T. A.. AU - Vierkant, R. A.. AU - Cunningham, J. C.. AU - Schildkraut, J. M.. AU - Berchuck, A.. AU - Moorman, P. G.. AU - Iversen, E. S.. AU - Cramer, D. W.. AU - Terry, K. L.. AU - Vitonis, A. F.. AU - Titus-Ernstoff, L.. AU - Song, ...
TY - JOUR. T1 - Ovarian cancer risk factors by tumor aggressiveness. T2 - An analysis from the Ovarian Cancer Cohort Consortium. AU - Fortner, Renee T.. AU - Poole, Elizabeth M.. AU - Wentzensen, Nicolas A.. AU - Trabert, Britton. AU - White, Emily. AU - Arslan, Alan A.. AU - Patel, Alpa. AU - Setiawan, V. Wendy. AU - Visvanathan, Kala. AU - Weiderpass, Elisabete. AU - Adami, Hans-Olov. AU - Black, Amanda. AU - Bernstein, Leslie. AU - Brinton, Louise A.. AU - Buring, Julie. AU - Clendenen, Tess. AU - Fournier, Agnes. AU - Fraser, Gary. AU - Gapstur, Susan M.. AU - Gaudet, Mia M.. AU - Giles, Graham G.. AU - Gram, Inger T.. AU - Hartge, Patricia. AU - Hoffman-Bolton, Judith. AU - Idahl, Annika. AU - Kaaks, Rudolf. AU - Kirsh, Victoria A.. AU - Knutsen, Synnove. AU - Koh, Woon-Puay. AU - Lacey, James V.. AU - Lee, I-Min. AU - Lundin, Eva. AU - Merritt, Melissa A.. AU - Milne, Roger L.. AU - Onland-Moret, N. Charlotte. AU - Peters, Ulrike. AU - Poynter, Jenny N.. AU - Rinaldi, Sabina. AU - Robien, ...
Epithelial ovarian cancer (EOC) is one of the leading causes of cancer deaths in women worldwide. Ubiquitin-conjugating enzyme 9 (Ubc9), the sole conjugating enzyme for sumoylation, regulates protein function and plays an important role in sumoylation-mediated cellular pathways. Although sumoylation plays a key role in DNA repair and tumorgenesis, whether Ubc9 is involved in EOC progression remains unknown. In the present study, we constructed Ubc-9 expressed recombined plasmid pEGFP-N1-Ubc9. The mRNA levels of Ubc9 were confirmed in human ovarian cell lines before and after transfection with pEGFP-N1-Ubc9 or small interfering RNA (siRNA) targeted Ubc9 by real-time polymerase chain reaction (PCR). The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to observe the effect of Ubc9 on cell proliferation. The protein levels of Ubc9, and proliferation-related signals Akt and physphorylated Akt were determined by Western blot. Our results showed that proliferation of EOC
Doctors give trusted, helpful answers on causes, diagnosis, symptoms, treatment, and more: Dr. Hashemi on ovarian granulosa cell tumor: Sperm in men (&testosterone) and eggs/ova in women (& estrogens), and these are also the sites of germ cell tumors. Outside the gonads, the mediastinum and brain (pineal) are the most common extragonadal sites. These are known to produce markers (hcg, alphafeto-protein) and responsve and curable with chemotherapy. Hope this helps.
The therapeutic effect of a combination of paclitaxel (PTX) and platinum (PLT) in ovarian clear cell adenocarcinoma (CC) patients with measurable disease has yet to be elucidated. In this study, we used retrospective review to evaluate the results of treatment with a combination of PTX and PLT in CC patients with measurable disease. A total of 28 patients with measurable residual CC (15 cases with primary disease, 13 cases with recurrent disease) treated with combination PTX-PLT chemotherapy was identified through medical records from ten institutions. Clinical response to chemotherapy was evaluated using Response Evaluation Criteria in Solid Tumors criteria. Of the 28 cases, 8 of 15 patients with primary disease (53.3%) and 3 of 13 patients with recurrent disease (23.1%) responded to PTX-PLT chemotherapy. The response rate for cases with late recurrent disease (,12 months) was 20% (1/5), whereas the rate was 25% (2/8) for cases with early recurrent (,12 months) or refractory disease. Our ...
Oncolytics Biotech Inc. (Oncolytics) announced today that patient enrolment has started in a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal and fallopian tube cancers using concurrent intravenous (IV) and intraperitoneal (IP)REOLYSIN®, Oncolytics proprietary formulation of the human reovirus. ... A cell with an activated Ras Pathway, which has lost its ability to…
Beamer, W G.; Shultz, K L.; Tennent, B J.; Azumi, N; and Sundberg, J P., Mouse model for malignant juvenile ovarian granulosa cell tumors. (1998). Faculty Research 1990 - 1999. 1160 ...
Despite increasing evidence that precision therapy targeted to the molecular drivers of a cancer has the potential to improve clinical outcomes, high-grade epithelial ovarian cancer (OC) patients are currently treated without consideration of molecular phenotype, and predictive biomarkers that could better inform treatment remain unknown. Delivery of precision therapy requires improved integration of laboratory-based models and cutting-edge clinical research, with pre-clinical models predicting patient subsets that will benefit from a particular targeted therapeutic. Patient-derived xenografts (PDXs) are renewable tumor models engrafted in mice, generated from fresh human tumors without prior in vitro exposure. PDX models allow an invaluable assessment of tumor evolution and adaptive response to therapy. PDX models have been applied to pre-clinical drug testing and biomarker identification in a number of cancers including ovarian, pancreatic, breast, and prostate cancers. These models have been shown to
A new study finds that young women with early stage ovarian cancer can preserve future fertility by keeping at least one ovary or the uterus without increasing the risk of dying from the disease.
Vascular endothelial growth factor (VEGF)-A inhibitors exhibit unseen high responses and toxicity in recurrent epithelial ovarian cancer suggesting an important role for the VEGF/VEGFR pathway. We studied the correlation of VEGF signalling and AKT/mTOR signalling. Using a tissue microarray of clinical samples (N=86), tumour cell immunohistochemical staining of AKT/mTOR downstream targets, pS6 and p4E-BP1, together with tumour cell staining of VEGF-A and pVEGFR2 were semi-quantified. A correlation was found between the marker for VEGFR2 activation (pVEGFR2) and a downstream target of AKT/mTOR signalling (pS6) (R=0.29; P=0.002). Additional gene expression analysis in an independent cDNA microarray dataset (N=24) showed a negative correlation (R=−0.73, P|0.0001) between the RPS6 and the VEGFR2 gene, which is consistent as the gene expression and phosphorylation of S6 is inversely regulated. An activated tumour cell VEGFR2/AKT/mTOR pathway was associated with increased incidence of ascites (χ2, P=0.002)
TY - JOUR. T1 - Ovarian clear cell adenocarcinoma revealed in a young patient during hormone therapy: a case report. AU - Kawai, Satoshi. AU - Ichikawa, Ryoko. AU - Ueda, Takahiro. AU - Urano, Makoto. AU - Kuroda, Makoto. AU - Fujii, Takuma. PY - 2016. Y1 - 2016. U2 - 10.20407/fmj.2.4_77. DO - 10.20407/fmj.2.4_77. M3 - Article. VL - 2. SP - 77. EP - 79. JO - Fujita medical journal. JF - Fujita medical journal. SN - 2189-7247. IS - 4. ER - ...
Learn how Avastin® (bevacizumab) works in recurrent platinum-treated ovarian cancer including platinum-resistant ovarian cancer (prOC) and platinum-sensitive ovarian cancer (psOC) Metastatic Colorectal Cancer (mCRC) Avastin is approved to treat metastatic colorectal cancer (mCRC) for: First- or second-line treatment in combination with intravenous 5-fluorouracil-based chemotherapy Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes Avastin. Avastin is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body. Glioblastoma (GBM) Avastin is approved to treat glioblastoma (GBM) when taken alone in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM). The effectiveness of Avastin in rGBM is based on tumor response. Currently, no data have shown whether or not Avastin improves disease
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This roadmap for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
Semaphorins comprise a family of molecules that influence neuronal growth and guidance. Class-3 semaphorins, semaphorin-3B (SEMA3B) and semaphorin-3F (SEMA3F), illustrate their effects by forming a complex with neuropilins (NP-1 or NP-2) and plexins. We examined the status and regulation of semaphorins and their receptors in human ovarian cancer cells. A significantly reduced expression of SEMA3B (83 kDa), SEMA3F (90 kDa), and plexin-A3 was observed in ovarian cancer cell lines when compared with normal human ovarian surface epithelial cells. The expression of NP-1, NP-2, and plexin-A1 was not altered in human ovarian surface epithelial and ovarian cancer cells. The decreased expression of SEMA3B, SEMA3F, and plexin-A3 was confirmed in stage 3 ovarian tumors. The treatment of ovarian cancer cells with luteinizing hormone, follicle-stimulating hormone, and estrogen induced a significant upregulation of SEMA3B, whereas SEMA3F was upregulated only by estrogen. Cotreatment of cell lines with a ...
Mutations of NH2-terminal β-catenin sequences have been demonstrated in various human tumor types, including colorectal carcinomas (24 , 39) , melanomas (40) , hepatoblastomas (41) , medulloblastomas (42) , prostatic carcinomas (43 , 44) , and uterine endometrial carcinomas (45, 46, 47, 48) , particularly endometrioid adenocarcinomas with squamous differentiation (10) . Prior studies of ovarian carcinomas have indicated that β-catenin mutations are common only in OEAs, with estimated mutation frequencies of 16-54% (10, 11, 12, 13, 14) .. We have pursued our studies of the prevalence and mechanisms underlying β-catenin deregulation in 45 histologically verified frozen primary OEA tissues. This is, in fact, a substantial number of primary tumors of this particular histological subtype, because only 10-20% of ovarian carcinomas are endometrioid (49) . We identified CTNNB1 exon 3 mutations in 31% of our primary ovarian endometrioid carcinomas. Mutations inactivating the APC, AXIN1, and AXIN2 ...
Many studies have compared open surgery and laparoscopic surgery in gynecology. Furthermore, several studies have compared conventional laparoscopy using multiple ports and laparotomy in ovarian cancer [9,18,19-21]. However, no previous study has compared single-port laparoscopic surgery and laparotomy in ovarian cancer, although several studies have compared single-port and multiport laparoscopic surgery for benign gynecologic diseases [13,22]. Therefore, this study is the first to investigate the feasibility of single-port laparoscopic surgery by comparing SPLS and staging laparotomy in early ovarian cancer.. According to our results, SPLS has several advantages in terms of surgical outcomes, such as lower estimated blood loss, lower transfusion rate, less postoperative pain, and shorter postoperative hospital stay, while showing no significant differences in survival outcomes. Less blood loss is well known as one of the main advantages of minimally invasive surgery. In this study, there was ...
TY - JOUR. T1 - The chemosensitivity of nodal metastases in recurrent epithelial ovarian cancer. AU - Kataoka, F.. AU - Tsuda, H.. AU - Nomura, H.. AU - Chiyoda, T.. AU - Tominaga, E.. AU - Suzuki, A.. AU - Susumu, N.. AU - Aoki, D.. PY - 2011/5/11. Y1 - 2011/5/11. N2 - Purpose: In this study, we compared second-line chemotherapy effects of nodal metastases with other metastases sites. Methods: The medical records of 44 women with recurrent ovarian cancer who received second-line chemotherapy were retrospectively reviewed. Results: Median age at the time of second-line chemotherapy was 55 years (range: 31-74). Recurrent sites were as follows: 29 patients had a solitary site (abdominal cavity: 8; lymph node: 3; pelvic cavity: 10; liver: 4; lung: 4) and 15 patients had multiple sites In total, the response rate was 30% (CR: 8, PR: 5). The response rate in sensitive cases was higher than in refractory/resistant cases (50% vs 5% p = 0.002). However, age, chemotherapy regimen, histologic type and ...
Inclusion Criteria:. - Have recurrent epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer. - Have platinum-resistant (recurrence within 6 months of a platinum-containing regimen) or platinum refractory (progression while on platinum) disease - Have measurable disease according to RECIST or detectable disease. o Measurable disease is defined as the presence of at least one uni-dimensionally measurable lesion greater than or equal to 20 mm by conventional techniques, including palpation, plain x-ray, CT scan or MRI, or greater than or equal to 10 mm by spiral CT scan. o Detectable disease is defined in a patient as one who does not have measurable disease but has at least one of the following conditions: 1) Baseline values of cancer antigen 125 (CA-125) at least twice the upper limit of normal; 2) Ascites and/or pleural effusion attributed to tumor; 3) solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST definitions for target lesions. ...
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with th …
Ovarian cancer is the leading cause of death from gynecologic cancer in women worldwide. According to the National Cancer Institute, ovarian cancer has the highest mortality rate among all the reproductive cancers in women. Advanced stage diagnosis and chemo/radio-resistance is a major obstacle in treating advanced ovarian cancer. The most commonly employed chemotherapeutic drug for ovarian cancer treatment is cis-platin. As with most chemotherapeutic drugs, many patients eventually become resistant to cis-platin and therefore, diminishing its effect. The efficacy of current treatments may be improved by increasing the sensitivity of cancer cells to chemo/radiation therapies. The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of
Objectives: Adherence to National Comprehensive Cancer Network (NCCN) guidelines for ovarian cancer treatment improves patient outcomes. The aim of this study was to assess disparities associated with ovarian cancer treatment in the state of Kentucky and central Appalachia. Methods: Data on patients diagnosed as having ovarian cancer from 2007 through 2011 were extracted from administrative...
The addition of bevacizumab (Avastin) to gemcitabine and carboplatin, followed by bevacizumab until disease progression, resulted in significantly improved progression-free survival compared to gemcitabine and carboplatin plus placebo among women with platinum-sensitive recurrent ovarian, primary periotoneal, or fallopian tube cancer. Results from the phase III OCEANS (Ovarian Cancer Study Comparing the Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive Recurrent Disease) trial were published in the Journal of Clinical Oncology.1 The study was sponsored by Genentech, which manufactures bevacizumab.. Analysis of Progression-free Survival. Both treatment groups consisted of 242 patients with histologically confirmed disease progression and ≥ 6 months after completion of front-line platinum-based chemotherapy. At the time of the final [progression-free survival] analysis (338 events), the median follow-up was 24 months, the authors reported. The median ...
Ovarian cancer affects the female ovaries, the part of the reproductive system that produces eggs. The cancer cells, in this case, originate in the lining of the ovaries. There are no special ovarian cancer signs and symptoms, but it may produce specific symptoms only when it travels to other nearly tissues and organs, including the pelvis and the stomach.. Last stage ovarian cancer is extremely difficult to treat. Ovarian cancer treatment options include chemotherapy and surgery. For the cancer cases that has spread extensively, a surgery is performed. During ovarian cancer surgery, both the ovaries are removed along with the Fallopian tubes and the uterus. In addition, some abdominal tissues and the nearby lymph nodes may also be removed.. Recovery after ovarian cancer surgery takes a few weeks. The patients is typically required to stay in the hospital for at least a week after the surgery.. ...
Dishevelled family proteins (DVL1, DVL2 and DVL3) are cytoplasmic mediators involved in canonical and non-canonical Wnt signaling that are important for embryonic development. Since Wnt signaling promotes cell proliferation and invasion, its increased activation is associated with cancer development as well. To get deeper insight into the behavior of Dishevelled proteins in cancer, we studied their expression in serous ovarian carcinomas [both low- (LGSC) and high-grade (HGSC)], and HGSC cell lines OVCAR5, OVCAR8 and OVSAHO. DVL protein expression in serous ovarian carcinomas tissues was analyzed using immunohistochemistry while DVL protein and mRNA expressions in HGSC cell lines were analyzed using western blot and quantitative real-time PCR. DVL1 protein expression was significantly higher in LGSC compared with normal ovarian tissue, while DVL3 was overexpressed in both LGSC and HGSC. DVL2 and DVL3 protein expression was higher in HGSC cell lines when compared with normal control cell line ...
A look at the following clinical trial: Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function.
The manganese superoxide dismutase (MnSOD), located in the mitochondria, is a major antioxidant enzyme that plays an important role in protecting cells from oxidative damage. MnSOD has been suggested to have tumor suppressor function in many cancer types. Surprisingly, the levels of MnSOD in ovarian carcinomas were found elevated compared with normal ovarian epithelium. In this study, we aimed to investigate the levels of MnSOD protein in ovarian cancer cell lines and ovarian surface epithelial (OSE) cells and a possible link between MnSOD expression and resistance to apoptosis. We showed that MnSOD protein was abundant in most ovarian cancer cell lines but was at very low levels in OSE. MnSOD overexpression in ovarian cancer cells caused a ~50% decrease of cell proliferation and an increase of apoptosis, whereas targeted inhibition of endogenous MnSOD using small interfering RNA promoted growth of these cells, confirming the effect was MnSOD specific. Furthermore, stimulation of mitochondrial ...
The effective treatment of ovarian serous carcinoma remains a major challenge because of the recurrence of platinum-resistant tumors. The mechanism of platinum-resistance may involve decreased cellular uptake caused by abnormalities of transporters, intracellular cisplatin inactivation (e.g., caused by glutathione), and increased DNA repair (18). However, no available therapy prevents platinum-resistance.. TBX2 is overexpressed by numerous human cancers (7-14). TBX2 may serve as a prognostic factor of breast cancer (7,9), melanoma (8), gastric cancer (10), prostate cancer (11), laryngeal squamous cell carcinoma (12), and non-small cell lung cancer (14). TBX2 is associated with resistance to therapeutic drugs such as cisplatin and doxorubicin (15,16), and TBX2 therefore may serve as a therapeutic target.. One report shows that chromosome 17q12-q24 harbors strong candidates for ovarian tumorigenesis, such as LASP1 (17q12), TGF11 (17q21.32), MUL (17q23.2), TBX2 (17q23.2), AXIN2 (17q24.3), and GRB2 ...
TY - JOUR. T1 - The mTORC2 Component Rictor Contributes to Cisplatin Resistance in Human Ovarian Cancer Cells. AU - Im-aram, Akechai. AU - Farrand, Lee. AU - Bae, Seung Min. AU - Song, Gwonhwa. AU - Song, Yong Sang. AU - Han, Jae Yong. AU - Tsang, Benjamin K.. PY - 2013/9/23. Y1 - 2013/9/23. N2 - Resistance to cisplatin-based therapy is a major cause of treatment failure in human ovarian cancer. A better understanding of the mechanisms of cisplatin resistance will offer new insights for novel therapeutic strategies for this deadly disease. Akt and p53 are determinants of cisplatin sensitivity. Rictor is a component of mTOR protein kinase complex 2, which is required for Akt phosphorylation (Ser473) and full activation. However, the precise role of rictor and the relationship between rictor and p53 in cisplatin resistance remains poorly understood. Here, using sensitive wild-type p53 (OV2008 and A2780s), resistant wild-type p53 (C13* and OVCAR433), and p53 compromised (A2780cp, OCC1, and SKOV-3) ...
Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines is valuable for development of therapeutic strategies to avoid platinum inefficacy and to exploit platinum sensitivity. TOV-21G devoid of FANCF expression, OV-90 and SKOV-3 were employed as examples of platinum-sensitive, platinum-intermediate and platinum-resistant cell lines, respectively. Antineoplastic agents examined included mitomycin C, doxorubicin, etoposide, gemcitabine, chlorambucil, paclitaxel, triapine and X-rays. Their effectiveness against cell lines was analyzed by clonogenic assays. Cytotoxic profiles of mitomycin C and carboplatin were similar, with mitomycin C exhibiting greater potency and selectivity against TOV-21G than carboplatin. Cytotoxic profiles of doxorubicin, etoposide and X-rays overlapped with that of ...